About 23 results found for searched term "SN-6" (0.051 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3771 | PSN632408 | GPR/FFAR |
| PSN632408 is a novel, selective and small-molecule agonist of human and mouse GPR119 with EC50 values of 5.6±0.99 μM and 7.9±0.7 μM, respectively. | ||
| M3773 | PSN 375963 | GPR/FFAR |
| PSN-375963 | ||
| PSN 375963 is an effective GPR119 agonist with EC50 of 8.4 and 7.9 μM for human and mice, respectively. PSN 375963 showed similar potency to endogenous oleoylethanolamide (OEA). | ||
| M5835 | Ondansetron Hydrochloride Dihydrate | 5-HT Receptor |
| GR 38032; SN 307; NSC 665799 | ||
| Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist (Ki=6.16 nM), with low affinity for dopamine receptors. | ||
| M8740 | SN-6 | Others |
| SN-6 is a selective inhibitor of Na+/Ca++ exchanger (NCX) with some selectivity for the NCX1 isoform. | ||
| M9130 | LSN3154567 | NAMPT |
| Nampt-IN-1 | ||
| LSN3154567 (also known as Nampt-IN-1) is a potent and elective NAMPT inhibitor, inhibits purified NAMPT with an IC50 of 3.1 nM. | ||
| M9681 | JBSNF-000088 (6-Methoxynicotinamide) | Others |
| 6-Methoxynicotinamide | ||
| Jbsnf-000088 (6-methoxynicotinamide) is a niacinamide (NA) analogue, which is a potent NNMT inhibitor. Jbsnf-000088 (6-methoxynicotinamide) is a niacinamide n-methyl transferase (NNMT) inhibitor. The IC50 of monkey NNMT and mouse NNMT were 1.8 µM, 2.8 µM and 5.0 µM, respectively. In animal models of metabolic diseases, JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization and regulates glucose. | ||
| M10896 | Vecabrutinib | BTK |
| SNS-062 | ||
| Vecabrutinib (SNS-062) is a potent, non-covalent BTK and ITK inhibitor,Kd The values are 0.3 nM and 2.2 nM, respectively. Vecabrutinib for ITK IC50 The value is 24 nM. | ||
| M13387 | Revumenib (SNDX-5613) | Epigenetic Reader Domain |
| SNDX5613 | ||
| Revumenib (SNDX-5613) is a first-in-class, effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Revumenib (SNDX-5613) can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). | ||
| M13600 | Abemaciclib metabolite M20 | CDK |
| LSN3106726 | ||
| Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer. | ||
| M13602 | Abemaciclib metabolite M18 hydrochloride | CDK |
| LSN3106729 hydrochloride | ||
| Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. | ||
| M14021 | Fezolinetant | Neurokinin Receptor |
| ESN-364 | ||
| Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes. | ||
| M14297 | Fidarestat | Others |
| SNK 860 | ||
| Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease. | ||
| M24957 | Axatilimab | CSF-1R (c-Fms) |
| SNDX-6352 | ||
| Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. | ||
| M28101 | BTK IN-1 | BTK |
| SNS062 analog | ||
| BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM. | ||
| M41832 | LSN3160440 | GLP Receptor |
| LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R. | ||
| M43387 | SN32976 | PI3K |
| SN32976 is a potent and selective class I PI3K and mTOR inhibitor with IC50s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. | ||
| M54710 | Senexin B | CDK |
| SNX2-1-165; BCD-115 | ||
| Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively. | ||
| M56790 | ASN06917370 | ROR |
| ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. | ||
| M56298 | SNC162 | Opioid Receptor |
| SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. | ||
| M56274 | LSN2463359 | GluR |
| LSN2463359 is positive allosteric modulator of metabotropic glutamate 5 (mGlu5). | ||
| M56199 | PSN 375963 hydrochloride | GPR/FFAR |
| PSN 375963 hydrochloride is a potent GPR119 agonist, with EC50s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. | ||
| M55794 | ASN03576800 | Anti-infection |
| ASN03576800 could be a potent inhibitor for Ebola virus matrix protein VP40 in process of viral assembly and budding process. | ||
| M58388 | Abemaciclib metabolites M2 | CDK |
| LSN2839567 | ||
| Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
